June 2004, Volume 34 Number 6 , p 30 - 30
© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(6) June 2004 p 30 Generic versions poised to compete [DRUG NEWS: OXYCONTIN]
The FDA has approved two generic versions of Oxycontin, a 12-hour oral formulation of oxycodone. The move is likely to save money for cancer patients and others who depend on Oxycontin for long-term analgesia.
An effective treatment for prolonged, severe pain, Oxycontin also has a high abuse potential. Intended to be swallowed whole, it causes a fast, dangerous “high” when chewed, injected, or snorted. Highly addictive and linked to more than 100 deaths, it carries the FDA's strongest warning label. The two generic manufacturers, Teva Pharmaceuticals and Endo Pharmaceuticals, will be required to provide the same warnings and safeguards that apply to Oxycontin, which is made by Purdue Pharma.
Patients who need Oxycontin around ...